MEDISAN Pharmaceuticals: In the third phase of the 2022 incentive plan, 166 individuals can lift the sales restrictions

The Supervisory Board of Harbin Sanlian Pharmaceutical Co., Ltd. reviewed the list of incentive objects eligible for the third release of restrictions under the 2022 Restricted Stock Incentive Plan. The verification showed that the company meets the conditions for implementing the equity incentive plan, has the qualifications as a subject, and there are no circumstances that would prevent the lifting of restrictions. The 166 incentive objects do not have any legal prohibitions against participating in the incentive, and they have met the conditions for lifting restrictions, with their qualifications being legal and valid. The Supervisory Board believes that the conditions for lifting restrictions have been fulfilled this time and agrees to handle the lifting of restrictions for 1,963,555 shares of restricted stock for the 166 incentive objects, with the announcement date being September 17, 2025